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Objectives: To explore contemporary antibiotic management of infections caused by carbapenem-
resistant Gram-negative bacteria in hospitals.
Methods: Cross-sectional, internet-based questionnaire survey. We contacted representatives of all
hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, Slovenia,
Spain and selected hospitals in the USA. We asked respondents to describe the most common actual
practice at their hospital regarding management of carbapenem-resistant Enterobacteriaceae, Acineto-
bacter baumannii and Pseudomonas aeruginosa through close-ended questions.
Results: Between January and June 2017, 115 of 141 eligible hospitals participated (overall response rate
81.6%, country-speciﬁc rates 66.7%e100%). Most were tertiary-care (99/114, 86.8%), university-afﬁliated
(110/115, 89.1%) hospitals and most representatives were infectious disease specialists (99/115, 86.1%).
Combination therapy was prescribed in 114/115 (99.1%) hospitals at least occasionally. Respondents were
more likely to consider combination therapy when treating bacteraemia, pneumonia and central nervous
system infections and for Enterobacteriaceae, P. aeruginosa and A. baumannii similarly. Combination of a
polymyxin with a carbapenem was used in most cases, whereas combinations of a polymyxin with
tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was used for
treatment of complicated urinary tract infections, usually with an aminoglycoside or a polymyxin. The
intended goal of combination therapy was to improve the effectiveness of the treatment and to prevent
development of resistance. In general, respondents shared the misconception that combination therapy
is supported by strong scientiﬁc evidence.fectious Diseases, University
lovenia.
tion.
biology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
L. Papst et al. / Clinical Microbiology and Infection 24 (2018) 1070e1076 1071Conclusions: Combination therapy was the preferred treatment strategy for infections caused by
carbapenem-resistant Gram-negative bacteria among hospital representatives, even though high-quality
evidence for carbapenem-based combination therapy is lacking. L. Papst, Clin Microbiol Infect
2018;24:1070
© 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Treatment of infections caused by carbapenem-resistant Gram-
negative bacilli (CRGNB) represents a difﬁcult challenge for physi-
cians because of the paucity of antibiotics active against these
bacteria and potential inferior efﬁcacy of the old drugs [1]. Mor-
tality rates are high and despite increasing incidence of these in-
fections worldwide there is no consensus on the most appropriate
treatment strategy due to lack of high-quality evidence from ran-
domized controlled trials (RCTs) [1,2].
In vitro studies suggest synergistic interactions between several
antibiotic combinations against CRGNBs. Combinations that have
shown synergy include colistin and rifampicin [3e5], carbapenem
and sulbactam [4], polymyxin and a carbapenem [6,7], tigecycline
and colistin [8], carbapenem and an aminoglycoside [9] and double
carbapenem combinations [10,11]. Interactions are dependent on
bacterial species (Enterobacteriaceae, Pseudomonas aeruginosa,
Acinetobacter baumannii), the inoculum and the mechanisms of
resistance [7].
Following these in vitro data, observational studies in the last
decade suggested that combination therapy with two or more
agents was associated with better outcomes compared with mon-
otherapy with an active antibiotic [12e15], at least in patients with
a high risk of death [16]. Unlike the in vitro studies, the observa-
tional studies commonly do not address deﬁned antibiotic combi-
nations [13]. Evaluating effectiveness from these studies is
complicated due to difﬁculties in avoiding selection bias, address-
ing confounding and assigning the treatment groups, as well as
poor adherence to the assigned regimen in clinical practice [17,18].
The aim of our cross-sectional questionnaire survey was to
explore how hospital infection specialists manage infections
caused by CRGNB in selected European countries, Israel and
selected hospitals in the USA. We wished to record the most
common antibiotic practices along with factors that inﬂuenced the
decision on antibiotic choice.Materials and methods
Survey design
The study was a cross-sectional internet-based questionnaire
survey on therapy for infections caused by CRGNB. The question-
naire was designed with closed-ended questions and distributed
using the SurveyMonkey® platform [19]. We requested information
on the specialty of the participant, hospital name, and size and type
of hospital. Questions on monotherapy, double combination and
triple combination therapy of infections caused by different
carbapenem-resistant bacteria followed [20]. Finally, the use of
carbapenems, polymyxins and tigecyclinewas investigated (the full
questionnaire is available in the Supplementary material). The
questionnaire was developed by two primary investigators (LP, MP)
and pre-tested by all authors for clarity and technical functionality.
Our target population comprised infectious diseases (ID), clin-
ical microbiology (CM) physicians or pharmacists treating patients,giving advice on antibiotic treatment or the professionals respon-
sible for the antimicrobial stewardship programme. We asked re-
spondents to reply describing the most common actual practice at
their hospital. Only one participant from a particular hospital was
included. In Europe and Israel we included all hospitals with more
than 800 acute-care hospital beds (medicine/surgery/obstetrics) in
countries reporting a high prevalence of CRGNB: France, Greece,
Israel, Italy, Kosovo, Slovenia and Spain. In the USA, we selected
hospitals where at least ten patients per year were treated with
polymyxins, based on surveys performed by KK for clinical studies
(Florida, Georgia, Illinois, Maryland, Michigan, New York, Penn-
sylvania, South Carolina).Survey administration
One investigator per country provided the list of all eligible
hospitals in the selected European countries, Israel and the USA.
One senior specialist (starting with the head of the infectious dis-
eases/clinical microbiology service or pharmacist specialized in
infectious diseases and antimicrobial stewardship) per hospital was
sent an invitation by the survey coordinator and the national
contact via email. If a response was not obtained we searched for
another contact person. Participants were able to access the ques-
tionnaire multiple times to allow for possible changes and
completion at later times.
The survey was voluntary, with no incentives offered to partic-
ipants (other than being listed as an investigator).Response rates
The unit measured with regards to the survey responses was the
hospital. Response rates were calculated as number of hospitals
from which an answer was recorded/total number of participating
hospitals, overall and per country. Information on hospital name
and country was used to screen for duplicate entries, but all data
were subsequently anonymized for the analyses.Statistical analysis
Both completed and partially completed questionnaires were
analysed using the number of completed responses per item as the
denominator.Results
The survey was administered between January and June 2017.
A total of 115 of 141 invited hospitals participated in the study
(overall response rate 81.6%, country-speciﬁc rates 66.7%e100%)
(see Supplementary material, Table S1). The vast majority of
respondents were ID specialists (99/115, 86.1%). Most partici-
pating centres were tertiary care (99/114, 86.8%) and university-
afﬁliated (110/115, 89.1%) hospitals (see Supplementary material,
Table S2).
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Almost half of the respondents (54/111, 48.6%) reported having
no guidelines regarding the treatment of infections caused by
CRGNB, with the remainder having local guidelines (19.8%), na-
tional guidelines (18.9%) or both (12.6%). Source of infection,
severity of the disease and the pathogenMIC for the antibiotic were
most frequently regarded as very important factors when choosing
the antibiotic regimen for the treatment of infections caused by
CRGNB (Table 1). The type of isolated microorganism and phar-
macokinetic/pharmacodynamic proﬁle of the antibiotic were also
considered important, whereas a patient's immune status was a
lesser determinant of treatment choice.
Antibiotics used
The polymyxin used in almost all participating hospitals was
colistin, most frequently dosed twice daily following a loading dose
of 9 million international units (Table 2). Therapeutic drug moni-
toring for polymyxins was routinely used in 5/112 (4.5%) hospitals
and was available for speciﬁc indications (e.g. renal failure) in 13/
112 (11.6%) hospitals. The use of aerosolized polymyxin was
frequent for ventilator-associated pneumonia (86/112, 76.8%). In
more than half of hospitals, tigecycline was used in higher doses
than approved: 200 mg daily in 54.5% (60/110) and 150 mg daily in
6.4% (7/110) of the hospitals. When included in combination ther-
apy, the most common carbapenem used was meropenem (100/
109, 91.7%) and prolonged infusions of carbapenems were
commonly used (Table 3). When asked about a MIC threshold for
carbapenem use for CRGNB, most respondents considered using a
carbapenem-containing combination when the carbapenem MIC
was 8 mg/L.
Combination therapy
Combination therapy was prescribed at least sometimes in 114/
115 (99.1%) hospitals. Respondents were more likely to consider
combination therapy when treating bacteraemia, pneumonia and
central nervous system infections and for Enterobactericeae,
P. aeruginosa and A. baumannii similarly (Table 4). When asked on
what the decision to use combination rather than monotherapy was
based, 63/110 (57.3%) declared they relied on in vitro studies, 69.1%
relied on observational studies, 55.5% relied on RCTs, 68.2% on sys-
tematic reviews and 53.6% on personal experience. The intended
goal of combination therapy was most commonly to improve the
effectiveness of the treatment (103/110, 93.6%) or to prevent devel-
opment of resistance (73.6%). Less commonly, combination therapy
was used to avoid toxicity through dose reduction (5.5%).Table 1
Importance of different factors when choosing an antibiotic for treating infections cause
Factor n (
No
Source of infection (e.g. pneumonia, urinary tract infection etc.) 1 (
Severity of the disease 2 (
Immune status of the patient 0 (
Renal or hepatic impairment 2 (
Type of isolated microorganism (e.g. Klebsiella pneumoniae,
Pseudomonas aeruginosa, etc.)
1 (
Type of carbapenemase (e.g. Klebsiella pneumoniae carbapenemase,
New Delhi metallo-b-lactamase etc.)
14
Minimum inhibitory concentration (MIC) for the antibiotic 2 (
Pharmacokinetic/pharmacodynamic proﬁle of the antibiotic 1 (
Toxicity proﬁle of the antibiotic 4 (
Interactions of the antibiotic with other drugs 15Carbapenem-resistant Enterobacteriaceae
Treatment strategies for infections caused by carbapenem-
resistant Enterobacteriaceae (CRE) are presented in Table 5. The
mechanisms of carbapenem resistance reported by respondents as
most frequent in their practice were production of Klebsiella
pneumoniae carbapenemase (KPC) (64%) and oxacillinase-48 (OXA-
48) (47.4%) (see Supplementary material, Table S3). Combination
therapy was a common strategy for treatment of CRE. When
monotherapy was considered, aminoglycosides (40/57, 70.2%) or
ceftazidime/avibactam (20/57, 35.1%) were used for complicated
urinary tract infections (cUTIs) and tigecycline was used
especially for intra-abdominal infections (IAIs) (20/57, 35.1%) and
skin and soft-tissue infections (SSTIs) (20/57, 35.1%). The most
popular choices for double combination therapy were combina-
tions of a polymyxin with a carbapenem (e.g. for treating bacter-
aemia in 63.9% (67/105) of hospitals) followed by a polymyxin with
tigecycline (e.g. for treating IAIs in 58.1% (61/105) of hospitals). For
treatment of IAIs and SSTIs, combinations of tigecycline with either
a carbapenem or an aminoglycoside were common and the com-
bination of an aminoglycoside with fosfomycin (34/105, 32.4%) was
often used for cUTIs. For triple combination therapy, a regimen
containing a polymyxin, tigecycline and either a carbapenem (e.g.
for treating bacteraemia in 55.6% (40/72) of hospitals) or an ami-
noglycoside (e.g. for treating bacteraemia in 29.2% (21/72) of hos-
pitals) was often used in participating hospitals.
Extensively drug-resistant carbapenem-resistant P. aeruginosa
Antibiotic choices for treatment of infections caused by exten-
sively drug-resistant carbapenem-resistant P. aeruginosa (XDR
CRPa) are shown in Table 6. Monotherapywas usedmostly for cUTIs
and ceftolozane/tazobactam (41/66, 62.1%) was the preferred op-
tion, followed by aminoglycosides (32/66, 48.5%) or polymyxins
(23/66, 34.8%). When treating with combination, a polymyxin was
usually used as a backbone with a carbapenem (e.g. for treating
bacteraemia in 54.7% (52/95) of hospitals), with an aminoglycoside
or fosfomycin added to it. For triple combination therapy a poly-
myxin and a carbapenem were usually combined with either fos-
fomycin or an aminoglycoside.
Extensively drug-resistant carbapenem-resistant A. baumannii
Treatment options for infections caused by extensively drug-
resistant carbapenem-resistant A. baumannii (XDR CRAb) are pre-
sented in Table 7. Monotherapy was used in 46/96 (47.9%) hospitals
and mainly for cUTIs. Aminoglycosides (29/46, 63%) and poly-
myxins (30/46, 65.2%) were the main treatment for cUTIs andd by carbapenem-resistant Gram-negative bacilli
%), N ¼ 110
t important Moderately important Very important
0.9) 15 (13.6) 94 (85.5)
1.8) 15 (13.6) 93 (84.5)
0) 50 (45.5) 60 (54.5)
1.8) 53 (48.2) 55 (50)
0.9) 25 (22.7) 84 (76.4)
(12.7) 38 (34.5) 58 (52.7)
1.8) 17 (15.5) 91 (82.7)
0.9) 24 (21.8) 85 (77.3)
3.6) 53 (48.2) 53 (48.2)
(13.6) 56 (50.9) 39 (35.5)
Table 2
Polymyxin use in participating centres
Characteristic Number of hospitals
Main polymyxin used N ¼ 112
Colistin 105 (93.8%)
Polymyxin B 1 (0.9%)
Both polymyxins 6 (5.4%)
Use of a loading dose 99/111 (89.2%) a
Colistin schedule b N ¼ 110
Twice daily 75 (68.2%)
Thrice daily 35 (31.8%)
Therapeutic drug monitoring (TDM) N ¼ 112
Routinely 5 (4.5%)
In speciﬁc situations 13 (11.6%)
Do not use 41 (36.6%)
No access to TDM for polymyxins 53 (47.3%)
Aerosolized polymyxin with systemic antibiotics
for ventilator-associated pneumonia
86/112 (76.8%)
a 9 million international units in 96 hospitals.
b Polymyxin B was given as a 2.5 or 3 mg/kg dose twice daily (n ¼ 6).
Table 3
Carbapenem-containing combination regimens for carbapenem-resistant Gram-
negative bacilli
Carbapenem used for combination therapy n (%), N ¼ 109
Doripenem 2 (1.8)
Imipenem 26 (23.9)
Meropenem 100 (91.7)
Ertapenem 7 (6.4)
Double-carbapenem combination therapy
(ertapenem combined with another carbapenem)
26 (23.9)
No carbapenem-containing combinations 8 (7.3)
Carbapenem MIC at which its use is considered n (%), N ¼ 106
MIC 4 mg/L 10 (9.4)
MIC 8 mg/L 47 (44.3)
MIC 16 mg/L 20 (18.9)
MIC 32 mg/L 10 (9.4)
Carbapenem use regardless of the MIC value 19 (17.9)
Use of prolonged carbapenem infusion in combinations n (%), N ¼ 105
Yes 76 (72.4)
No 29 (27.6)
Table 4
Indications for use of combination therapy
Source of infection n (%), N ¼ 110
Complicated urinary tract infections 41 (37.3)
Pneumonia 92 (83.6)
Intra-abdominal infections 80 (72.7)
Skin and soft-tissue infections 42 (38.2)
Central nervous system infections 96 (87.3)
Bacteraemia of any source 91 (82.7)
Bacteria n (%), N ¼ 109
Carbapenem-resistant Enterobacteriaceae 98 (89.9)
Carbapenem-resistant extensively drug-resistant
Pseudomonas aeruginosa
93 (85.3)
Carbapenem-resistant extensively drug-resistant
Acinetobacter baumannii
90 (82.5)
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double combination therapy for infections caused by CRAb. Com-
binations of a polymyxin with a carbapenem (e.g. for treating
bacteraemia in 60% (48/80) of hospitals) were most frequently
followed by a polymyxin combined with either tigecycline or
rifampin. Triple combination therapy was as commonly used as
monotherapy; a polymyxin plus tigecycline with a carbapenem or
rifampicin were the preferred choices.Differences between participating countries
Israel was the only country where monotherapy was the
preferred choice of treatment for infections caused by CRGNB, inall other countries combination therapy, usually the association of
two antibiotics, was the standard of care. However, monotherapy
for cUTIs was also very common in Kosovo, Slovenia, Spain and the
USA. There were no major differences in the selection of most
commonly used antibiotics, but some distinctions between
countries were noted. Ceftolozane/tazobactam was commonly
used for treatment of cUTIs and pneumonia caused by XDR CRPa in
France, Italy, Spain and the USA, whereas ceftazidime/avibactam
was used often for treatment of infections caused by CRE in the
USA. Polymyxin B was used only in some hospitals in the USA,
all other hospitals used colistin. These differences were dictated
by availability, as ceftolozane/tazobactam, ceftazidime/
avibactam, polymyxin B and intravenous fosfomycin were not
available in all countries at the time of the survey. Country level
data are presented in detail in the Supplementary material
(Tables S7eS14).
Discussion
The aim of our survey was to explore treatment regimens for
infections caused by CRGNB used by hospital infection specialists in
various countries. Our results show that source of infection,
severity of the disease and the MIC for the antibiotic were the most
important factors inﬂuencing the antibiotic choice. Double com-
bination therapy was the preferred strategy for CRGNB infections,
especially when treating bacteraemia, pneumonia and central
nervous system infections. Combination of a polymyxin with a
carbapenem was used in most cases, whereas combinations of a
polymyxin with tigecycline, an aminoglycoside, fosfomycin or
rifampicin were also common. Monotherapy was mainly used for
treatment of cUTIs, usually with an aminoglycoside or a polymyxin.
Ceftazidime/avibactam, approved by the US Food and Drug
Administration at the time of the survey but not yet by the Euro-
pean Medical Association, was often used for monotherapy of in-
fections caused by CRE in USA, whereas ceftolozane/tazobactam
was used for monotherapy of infections caused by XDR CRPa in
all countries except Israel. Among polymyxins, colistin was
almost universally used, mostly dosed twice daily after the initial
9 million international units loading dose. In more than 10% of
the hospitals a loading dose was not used. Participants felt
comfortable adding a carbapenem when the MIC was 8 mg/L,
and carbapenems were commonly administered in prolonged
infusions. Tigecycline was generally used for treating IAIs and
SSTIs, often in higher-than-approved doses.
In general, respondents shared the misconception that combi-
nation therapy is supported by strong scientiﬁc evidence (i.e. RCTs).
In fact, there were three RCTs published at the time of the survey
that tested only two interventions, only for A. baumanniidcolistin/
rifampicin versus colistin [21,22] and colistin/fosfomycin versus
colistin [23]. There were no published RCTs on carbapenem com-
bination therapy for CRGNBs (two underway at the time of the
survey: NCT01732250, NCT01597973). Many participants relied on
systematic reviews; systematic reviews of observational studies do
not necessarily provide better evidence than the included studies. A
recent systematic review graded the quality of the evidence on
combination therapy for CRGNBs as very low-quality data that
should not be used in guideline development or to support a
recommendation [18].
Clinical studies do not always mirror the results of in vitro
studies [24]. Exact bacterial inoculum and antibiotic doses can be
easily simultaneously assessed on agar plates but this may not be
replicated in an individual with sepsis. Even if combination therapy
were to be timed perfectly, drug penetration to the site of infection
cannot be controlled. Despite many in vitro studies demonstrating
synergistic interactions and prevention of resistant strain
Table 5
Most frequent antibiotic regimens for targeted treatment for infections caused by carbapenem-resistant Enterobacteriaceae a
Total N ¼ 114 cUTI Pneumonia IAI SSTI CNSI Bacteraemia
Monotherapy (N ¼ 57, 50%)
POL 20 (35.1) 18 (31.6) 10 (17.5) 12 (21.2) 7 (12.3) 17 (29.8)
TIG 5 (8.8) 9 (15.8) 20 (35.1) 20 (35.1) 3 (5.3) 8 (14)
AMG 40 (70.2) 6 (10.5) 8 (14) 7 (12.3) 3 (5.3) 14 (24.6)
FOS 19 (33.3) 1 (1.8) 1 (1.8) 0 (0) 3 (5.3) 3 (5.3)
CAZ/AVI 20 (35.1) 16 (28.1) 17 (29.8) 16 (28.1) 5 (8.8) 17 (29.8)
Double combination therapy (N ¼ 105, 92.1%)
POL þ TIG 13 (10) 43 (41) 61 (58.1) 40 (38.1) 9 (8.6) 34 (32.4)
POL þ CARB 53 (50.5) 63 (60) 52 (49.5) 35 (33.3) 52 (49.5) 67 (63.9)
TIG þ CARB 6 (5.7) 24 (22.9) 40 (38.1) 26 (24.8) 9 (8.6) 21 (20)
TIG þ AMG 9 (8.6) 12 (11.4) 32 (30.5) 26 (24.8) 3 (2.9) 18 (17.1)
AMG þ FOS 34 (32.4) 8 (7.6) 8 (7.6) 8 (7.6) 7 (6.7) 18 (17.1)
Triple combination therapy (N ¼ 72, 63.2%)
POL þ TIG þ CARB 12 (16.7) 39 (54.2) 36 (50) 22 (30.6) 21 (29.2) 40 (55.6)
POL þ TIG þ AMG 9 (12.5) 17 (23.6) 17 (23.6) 6 (8.3) 6 (8.3) 21 (29.2)
POL þ TIG þ FOS 4 (5.6) 14 (19.4) 8 (11.1) 6 (8.3) 8 (11.1) 13 (18.1)
POL þ AMG þ FOS 17 (23.6) 7 (9.7) 4 (5.6) 2 (2.8) 4 (5.6) 15 (20.8)
Double CARB þ POL 8 (11.1) 11 (15.3) 7 (9.7) 5 (6.9) 12 (16.7) 13 (18.1)
Abbreviations: cUTI, complicated urinary tract infection; IAI, intra-abdominal infection; SSTI, skin and soft-tissue infection; CNSI, central nervous system infection; POL,
polymyxin; TIG, tigecycline; AMG, aminoglycoside; FOS, fosfomycin; CAZ/AVI, ceftazidime/avibactam; CARB, carbapenem.
a Respondents could choose more than one treatment regimen. Detailed data on all antibiotic regimens are presented in the Supplementary material (Table S4).
Table 6
Most frequent antibiotic regimens for targeted treatment of infections caused by extensively drug-resistant carbapenem-resistant Pseudomonas aeruginosaa
Total N ¼ 110 cUTI Pneumonia IAI SSTI CNSI Bacteraemia
Monotherapy (N ¼ 66, 60%)
POL 23 (34.8) 15 (22.7) 12 (18.2) 14 (21.2) 7 (10.6) 13 (19.7)
AMG 32 (48.5) 4 (6.1) 6 (9.1) 5 (7.6) 1 (1.5) 8 (12.1)
FOS 11 (16.7) 0 (0) 0 (0) 1 (1.5) 1 (1.5) 1 (1.5)
TOL/TAZ 41 (62.1) 27 (40.9) 28 (42.4) 23 (34.8) 10 (15.2) 20 (30.3)
Double combination therapy (N ¼ 95, 86.4%)
POL þ CARB 41 (43.2) 58 (61.1) 51 (53.7) 40 (42.1) 43 (45.2) 52 (54.7)
POL þ RIF 6 (6.3) 15 (15.8) 9 (9.5) 10 (10.5) 12 (12.6) 13 (13.7)
POL þ AMG 33 (34.7) 27 (28.4) 32 (33.7) 23 (24.2) 9 (9.5) 35 (36.8)
POL þ FOS 30 (31.6) 26 (27.4) 18 (18.9) 19 (20) 15 (15.8) 22 (23.2)
AMG þ FOS 30 (31.6) 12 (12.6) 11 (11.6) 12 (12.6) 7 (7.4) 16 (16.8)
Triple combination therapy (N ¼ 48, 43.6%)
POL þ CARB þ RIF 7 (14.6) 17 (35.4) 14 (29.2) 13 (27.1) 16 (33.3) 15 (31.3)
POL þ CARB þ AMG 15 (31.3) 16 (33.3) 16 (33.3) 13 (27.1) 9 (18.8) 20 (41.7)
POL þ CARB þ FOS 17 (35.4) 12 (25) 10 (20.8) 9 (18.8) 14 (29.2) 12 (25)
POL þ AMG þ RIF 5 (10.4) 4 (8.3) 7 (14.6) 5 (10.4) 8 (16.7) 11 (22.9)
POL þ AMG þ FOS 12 (25) 9 (18.8) 6 (12.5) 5 (10.4) 7 (14.6) 10 (20.8)
Abbreviations: cUTI, complicated urinary tract infection; IAI, intra-abdominal infection; SSTI, skin and soft-tissue infection; CNSI, central nervous system infection; POL,
polymyxin; AMG, aminoglycoside; FOS, fosfomycin; TOL/TAZ, ceftolozane/tazobactam; CARB, carbapenem; RIF, rifampicin.
a Respondents could choose more than one treatment regimen. Detailed data on all antibiotic regimens are presented in the Supplementary material (Table S5).
Table 7
Most frequent antibiotic regimens for targeted treatment of infections caused by extensively drug-resistant carbapenem-resistant Acinetobacter baumannii a
Total N ¼ 96 cUTI Pneumonia IAI SSTI CNSI Bacteraemia
Monotherapy (N ¼ 46, 47.9%)
POL 30 (65.2) 21 (45.7) 16 (34.8) 18 (39.1) 13 (28.3) 19 (41.3)
TIG 4 (8.7) 5 (10.9) 14 (30.4) 16 (34.8) 1 (2.2) 3 (6.5)
AMG 29 (63) 5 (10.9) 5 (10.9) 5 (10.9) 1 (2.2) 9 (19.6)
Double combination therapy (N ¼ 80, 83.3%)
POL þ TIG 18 (22.5) 37 (46.3) 39 (48.8) 33 (41.3) 8 (10) 26 (32.5)
POL þ CARB 35 (43.8) 42 (52.5) 40 (50) 33 (41.3) 35 (43.8) 48 (60)
POL þ RIF 15 (18.8) 24 (30) 15 (18.8) 15 (18.8) 17 (21.3) 19 (23.8)
POL þ FOS 20 (25) 16 (20) 9 (11.3) 11 (13.8) 10 (12.5) 14 (17.5)
TIG þ CARB 4 (5) 14 (17.5) 19 (23.8) 14 (17.5) 7 (8.8) 13 (16.3)
Triple combination therapy (N ¼ 43, 44.8%)
POL þ TIG þ CARB 13 (30.2) 24 (55.8) 24 (55.8) 18 (41.9) 15 (34.9) 22 (51.2)
POL þ TIG þ RIF 7 (16.3) 18 (41.9) 13 (30.2) 15 (34.9) 11 (25.6) 14 (32.6)
POL þ TIG þ AMG 5 (11.6) 8 (18.6) 10 (23.2) 7 (16.3) 5 (11.6) 15 (34.9)
POL þ TIG þ FOS 6 (14) 7 (16.3) 9 (20.9) 6 (14) 7 (16.3) 7 (16.3)
TIG þ RIF þ AMG 5 (11.6) 5 (11.6) 7 (16.3) 7 (16.3) 2 (4.7) 9 (20.9)
Abbreviations: cUTI, complicated urinary tract infection; IAI, intra-abdominal infection; SSTI, skin and soft-tissue infection; CNSI, central nervous system infection; POL,
polymyxin; TIG, tigecycline; AMG, aminoglycoside; CARB, carbapenem; RIF, rifampicin; FOS, fosfomycin.
a Respondents could choose more than one treatment regimen. Detailed data on all antibiotic regimens are presented in the Supplementary material (Table S6).
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against Gram-negative bacteria, clinical studies failed to prove
clinical beneﬁts and there is no clinical demonstration of less
resistance with the combination [25e28]. Indeed, the only RCTs to
date of combination therapy for CRGNBs did not demonstrate
reduced mortality or clinical failure with combination therapy
[21e23].
Carbapenems, mainly meropenem, were the most common
antibiotics added to polymyxins in combination therapy regimens.
Carbapenems are among the antibiotics most commonly associ-
ated with Clostridium difﬁcile diarrhoea [29]. An even graver
consequence of carbapenem treatment is induction of carbape-
nem resistance and selection of carbapenem-resistant strains.
Studies show that carbapenem use is one of the most important
risk factors for colonization and infection with CRGNB [30]. With
carbapenem use as one of the main drivers of carbapenem resis-
tance its routine use as part of the combination therapy for
CRGNB infections in the absence of good-quality data remains
questionable.
The strength of this survey is a high response rate, giving an
insight into everyday practices of infection specialists dealing with
CRGNB infections in participating countries.We restricted inclusion
to large hospitals in Europe, since these hospitals are more likely to
care for patients with severe CRGNB infections. The main limitation
is that we did not access actual antibiotic prescription data, but
relied on a hospital representative. Responses might reﬂect per-
sonal opinion of participants on treatment strategies. However, we
made it clear in the online survey and in correspondence with re-
spondents that the survey intended to reﬂect actual common
practice at the participating hospital.
In conclusion, combination therapy is the preferred treatment
strategy for infections caused by CRGNB even though high-quality
evidence (supporting or not supporting this approach) are lack-
ing. The absence of good-quality studies, guidelines and recom-
mendations resulted in a myriad of combination antibiotic
regimens recorded in the survey. In the era of ever-growing car-
bapenem resistance, good-quality studies (especially RCTs) are ur-
gently needed to ascertain the most effective treatment strategies
regarding CRGNB infections. Evidence-based ESCMID guidelines on
the treatment of infections caused by multidrug-resistant Gram-
negative bacilli are to be published in 2018 and might help to
standardize the management of CRGNBs.
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